HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research note ...

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have been assigned a consensus recommendation of ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.09, accompanied by a high estimate of $10.00 and a low estimate of $2.00. Surpassing ...

Editor’s note: A breaking-news bulletin linked to this story inaccurately characterized the number of years that have passed since Sangamo Therapeutics shares lost as much in a single session.

It has been a little over a year since my previous Sangamo Therapeutics (NASDAQ:SGMO) article, where I discussed my cautious optimism regarding Sangamo’s ability to grind forward and work with ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target ...

Truist analyst Nicole Germino lowered the firm’s price target on Sangamo (SGMO) to $5 from $7 and keeps a Buy rating on the shares. The firm ...

In the last three months, 11 analysts have published ratings on Sangamo Therapeutics (NASDAQ:SGMO), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...